Advertisement
OtherArticle

Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans

Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
Drug Metabolism and Disposition January 18, 2023, DMD-AR-2022-001099; DOI: https://doi.org/10.1124/dmd.122.001099
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherArticle

Biotransformation of AZD4831 in animals and humans

Ulrik Jurva, Lars Weidolf, Ann-Sofie Sandinge, Carina Leandersson, Anja Ekdahl, Xue-Qing Li, Thomas Antonsson, Johan Sundell, Kristina Westerlund, Carl Amilon, Tord Inghardt and V. Sashi Gopaul
Drug Metabolism and Disposition January 18, 2023, DMD-AR-2022-001099; DOI: https://doi.org/10.1124/dmd.122.001099
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement